Occult Hepatitis B in Hemodialysis Patients

Objectives: We aimed to detect occult hepatitis B (OHB) in hemodialysis patients at a higher-risk for OHB

Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients

Aim of the study: The quantitative hepatitis B surface antigen (qHBsAg) level indicates the amount of transcriptional activity of covalently closed circular DNA (cccDNA) and integrated DNA in hepatocytes which plays a role in development of chronic hepatitis B (CHB) and may help decide whether the treatment is necessary or not. The aim of this study is to evaluate the association between serum qHBsAg levels and viral replication and stage of liver fibrosis in treatment-naive CHB patients and to determine the role of qHBsAg levels in predicting when liver biopsy is necessary

The Role of the Basal Core Promoter (BCP) and Precore Codon 28 Mutations in the Treatment Response to the Pegylated Interferon

Objective: Pegylated interferon has an important place in chronic hepatitis treatment and there are many factors affecting treatment response. Among these factors, studies on viral genomic mutations increase recently. In this study we aimed to determine the effects of precore and basal core promoter (BCP) mutations on the response to peg-interferon treatment treatment in patients received interferon treatment with the diagnosis of chronic hepatitis B